Author

Bronwyn Moore

Observed name: B. Moore

Observed institution: Concordia University

OpenAlex ID: A5058186490

Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation

2024 · Nilanjan Ghosh, Ruibin Wang, et al. · Blood Neoplasia · 9

Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone ( DRd ) Versus Bortezomib, Lenalidomide, and Dexamethasone ( VRd ) Among Transplant‐Ineligible Patients With Multiple Myeloma

2024 · Doris K. Hansen, Santosh Gautam, et al. · Cancer Medicine · 7

Identification of cytokine release syndrome and indicators of severity in retrospective databases among patients receiving immunotherapy

2024 · Scott F. Huntington, Dee Lin, et al. · Pharmacology Research & Perspectives · 5

Ibrutinib Dose Adjustment Does Not Impact Time to Next Treatment in First-Line Patients with Chronic Lymphocytic Leukemia: A Real-World Analysis of Electronic Medical Records from Academic and Non-Teaching Hospitals Using Target Trial Emulation

2023 · Nilanjan Ghosh, Zaina P Qureshi, et al. · Blood · 5

Real-World Clinical Outcomes and Treatment Patterns Among Black and Non-Black Patients With Prostate Cancer Initiated on Apalutamide in a Urology Setting

2024 · Benjamin H. Lowentritt, Carmine Rossi, et al. · Journal of health economics and outcomes research · 4

Mp29-14 Prostate-specific Antigen Response and Time-to-castration Resistance Among Patients With Metastatic Castration Sensitive Prostate Cancer Initiated on Apalutamide, Enzalutamide, or Abiraterone Acetate

2023 · Benjamin Lowentritt, Shawn Du, et al. · The Journal of Urology · 4

Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma

2023 · Doris K. Hansen, Santosh Gautam, et al. · Blood · 3

Patient Characteristics, Treatment Patterns and Early Outcomes of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Initiated on Talquetamab: An Electronic Medical Record and Chart Review Study

2024 · Cesar Rodriguez, Hsien-Yen Chang, et al. · Blood · 2

Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma

2025 · Santosh Gautam, Laura Morrison, et al. · Journal of Managed Care & Specialty Pharmacy · 1

Cost per Responder Model of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) for Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma

2025 · Santosh Gautam, Laura Morrison, et al. · Clinical Lymphoma Myeloma & Leukemia

Total Medical and Pharmacy Costs for Patients With Metastatic Castration- Sensitive Prostate Cancer Initiating Oral Androgen Receptor Pathway Inhibitors in the United States

2025 · Ibrahim Khilfeh, Carmine Rossi, et al. · Journal of Clinical Pathways

CO27 Real-World Treatment Response and Persistence Among Black and Non-Black Patients with Metastatic Castration-Sensitive Prostate Cancer Treated with Apalutamide in a Urology Setting

2023 · B. Lowentritt, S. Du, et al. · Value in Health

Real-world prostate-specific antigen (PSA) response and disease progression among patients with non-metastatic castration-resistant prostate cancer (nmCRPC) initiated on apalutamide (APA).

2023 · Benjamin H Lowentritt, Shawn Du, et al. · Journal of Clinical Oncology

Works count: 13

Citation count: 40

H-index: 4

I10-index: